
Akebia Therapeutics Announces New Chief Financial Officer



Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023.

Ms. Snow will join Akebia from Pear Therapeutics, Inc., where she has served as Chief Accounting Officer since 2021. Ms. Snow brings years of accounting and financial management expertise to her role at Akebia as the company executes its operating plan, which includes supporting the launch of Vafseo® (vadadustat) in Europe through Akebia's partner Medice and preparing to resubmit a New Drug Application (NDA) for vadadustat in the U.S.

"Ellen has built a reputation for driving financial discipline, strategic financial management, and most importantly, strong and committed leadership," said [John P. Butler](#), Chief Executive Officer of Akebia. "I'm thrilled to welcome Ellen to Akebia. The qualities and expertise she brings will be critical as we move toward a potential launch of vadadustat in the U.S. if approved."

Ms. Snow commented, "I'm excited to be joining Akebia at this pivotal stage of its evolution with catalysts ahead, including the clear path forward to resubmit the NDA for a potential approval of vadadustat. Akebia is a purpose-driven company with patients at the center of all they do, a core value that has also guided me. I am equally excited to work with the talented team at Akebia to achieve our goals."

Ms. Snow will succeed David A. Spellman, who served as Akebia's Senior Vice President, Chief Financial Officer and Treasurer since 2020.

[John Butler](#) added, "On behalf of our Board and our team at Akebia, I want to thank Dave for his contributions, meeting objectives that we believe well position Akebia financially to achieve important milestones ahead and invest in our future."

Prior to joining Pear Therapeutics, Inc., Ms. Snow served as the Chief Accounting Officer of AlerisLife Inc., a senior living and lifestyle services company, from 2019 to 2021. From 2016 to 2018, Ms. Snow served as the Vice President of Finance and Corporate Controller of Anika Therapeutics, Inc., a global joint preservation company. Prior to joining Anika Therapeutics, Inc., Ms. Snow served in various positions at Benchmark Senior Living, Bain Willard Companies, L.P., PricewaterhouseCoopers LLP and Ernst & Young LLP and as a financial consultant. Ms. Snow is a C.P.A. and holds a B.S. in Business Administration with a concentration in accounting from Merrimack College. She also completed the High Potentials Leadership Program at Harvard Business School.

Source: [Akebia Therapeutics®, Inc.](#)

Published on : Tue, 13 Jun 2023